Pyrimidin-4-bromobenzenesulfonamide/-4-nitrobenzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations.

Abstract excerpt

BRAF mutations were first discovered by Davies et al. in 2002. BRAFV600E mutation is the most prevalent, accounting for approximately 90% of all BRAF mutations. BRAFV600E mutations have been identified at varying frequencies across multiple human cancers, including malignant melanoma (70-90%), thyroid cancer (45-50%), colorectal cancer (5-20%), and others. In this study, we designed a series of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Molecular Docking Simulation